Generic Drug User Fees Lower Than Expected, Thanks To Higher Volume
This article was originally published in The Pink Sheet Daily
Executive Summary
Fiscal year 2013 fees for new ANDAs, prior approval supplements, backlogged applications and drug master files are 3%-50% below the agency’s initial projections.